SESSION 3: AGGRESSIVE LYMPHOMAS
CLONAL HEMATOPOIESIS IS ASSOCIATED WITH INFERIOR PROGNOSIS IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS abstract
J Boegeholz, S Alig, B Sworder, C Macaulay, et al.
The study authors conclude that In their study CHIP mutations were detected in 12.4% of DLBCL patients. While CHIP is associated with lower response rates and inferior survival outcomes after frontline cytotoxic therapy of DLBCL, this effect appears context-specific, since it was not observed in the rrDLBCL patients treated with CART19. The mutational CHIP landscape differed between their 2 cohorts, suggesting that cytotoxic therapy shapes CHIP evolution.
WHOLE GENOME SEQUENCING OF MATCHED PRIMARY AND RELAPSED DLBCL REVEALS DISTINCT EVOLUTIONARY DYNAMICS ASSOCIATED WITH RELAPSE TIMING abstract
L. K Hilton, B Collinge, C. K Rushton, S Ben-Neriah, et al.
The study authors conclude that in contrast to REFR DLBCL, LR tumors frequently represent new disease with significant genetic divergence yet shared biology with the primary disease. They further conclude that this is consistent with the hypothesis that DLBCLs arising from a common progenitor undergo convergent evolution and rely on common oncogenic pathways while also providing an explanation for the more frequent retained chemosensitivity in later DLBCL recurrence.
PHASED VARIANTS IMPROVE DLBCL MINIMAL RESIDUAL DISEASE DETECTION AT THE END OF THERAPY abstract
D. M Kurtz, J. J Chabon, J Soo, L Co Ting Keh, et al.
The study authors conclude that tracking PVs results in significantly lower background rates than SNV-based approaches, enabling detection to parts per million range. PhasED-Seq improves disease detection in DLBCL at the EOT, suggesting it is ideal for use in MRD-driven consolidative approaches.
GENETIC SUBTYPE GUIDED RITUXIMAB-BASED IMMUNOCHEMOTHERAPY IMPROVES OUTCOME IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA: FIRST REPORT OF A RANDOMIZED PHASE 2 STUDY abstract
M Zhang, P Xu, L Wang, S Cheng, W Zhao
The study authors conclude that genetic subtype guided R-CHOP-X showed encouraging response and outcome in DLBCL.
BIOMARKER-DRIVEN TREATMENT STRATEGY IN HIGH RISK DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS OF A NORDIC PHASE 2 STUDY abstract
S Leppä, J Jørgensen, M-L Karjalainen-Lindsberg, K Beiske, et al.
The study authors conclude that stratification according to biological risk factors is feasible and DA-EPOCH-R can overcome the adverse impact of biological risk factors, apart from 17p/p53 deletion and CD5+.
LONG-TERM ANALYSES FROM L-MIND, A PHASE II STUDY OF TAFASITAMAB PLUS LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) abstract
J Duell, K. J Maddocks, E González-Barca, W Jurczak, et al.
The study authors conclude that with a median duration of response of 43.9 months (NR for patients achieving a CR), combination therapy with tafasitamab + LEN followed by tafasitamab monotherapy provided durable responses in patients with R/R DLBCL not eligible for ASCT, with a manageable safety profile. These long-term data indicate that this chemotherapy-free regimen can achieve prolonged disease control and survival benefit in this patient population, especially at first relapse.